132089-36-2

Basic information

• Product Name: 2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: ethyl 2-(2-chlorophenyl)-1,3-thiazole-4-carboxylate;ethyl 2-(2-chlorophenyl)thiazol-4-carboxylate;2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER;ethyl 2-(2-chlorophenyl)thiazole-4-carboxylate
• CAS NO: 132089-36-2
• Molecular Formula: C₁₂H₁₀ClNO₂S
• Molecular Weight: 267.73
• EINECS: 604-604-1
• Mol File: 132089-36-2.mol

Chemical Properties

• Boiling Point: 396.594°C at 760 mmHg
• Flash Point: 193.654°C
• Appearance: /
• Density: 1.314g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(132089-36-2)
• EPA Substance Registry System: 2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(132089-36-2)

Safety Data

• Hazardous Substances Data: 132089-36-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER is used as a building block for the synthesis of various drugs and pharmaceuticals. Its chemical structure allows for the development of compounds with a range of biological activities, which is of significant interest for medicinal research.
Used in Drug Delivery Systems:
The ethyl ester group in 2-(2-CHLORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER makes it suitable for use in lipophilic environments and for encapsulation in drug delivery systems. This enhances the compound's potential for targeted drug delivery and improves the bioavailability of the synthesized pharmaceuticals.

InChI:InChI=1/C12H10ClNO2S/c1-2-16-12(15)10-7-17-11(14-10)8-5-3-4-6-9(8)13/h3-7H,2H2,1H3

Upstream product

• 673476-96-5 (2-chloro-phenyl)-thioacetic acid amide 
• 15717-17-6 2-chlorothiobenzamide 
• 100367-77-9 ethyl 2-bromothiazole-4-carboxylate 
• 3900-89-8 2-Chlorobenzeneboronic acid 
• 70-23-5 ethyl Bromopyruvate 
• 609-66-5 2-chlorobenzamide 
• 873-32-5 2-Chlorobenzonitrile 

Downstream Products

• 1338375-38-4 2-(2-chlorophenyl)-1,3-thiazole-4-carbohydrazide 
• 639517-84-3 [2-(2-chlorophenyl)-1,3-thiazol-4-yl]carboxyaldehyde 
• 639517-86-5 2-(2-chlorophenyl)-4-hydroxymethylthiazole 
• 944275-21-2 2-(2-chlorophenyl)thiazole-4-carboxylic acid 

Relevant articles and documents

Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists

Free fatty acid receptor 2 (FFA2), also known as GPR43, is activated by short-chain fatty acids (SCFAs) that are mainly produced by the gut microbiota through the fermentation of undigested carbohydrates and dietary fibers. FFA2 currently appears to be a

Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new oxadiazole and thiazole analogs

A series of 2-adamantyl-5-arylthiazolyl-1,3,4-oxadiazoles 7a–x together with thiazoles 13 and 14 were synthesized. Compounds 7a–l, 13, and 14 were tested in vitro with the aim of identifying novel lead compounds active against human immunodeficiency virus type-1 and human immunodeficiency virus type-2 activity in MT-4 cells. Title compounds were also tested against representatives of Gram-positive and Gram-negative bacteria (Staphylococcus aureus, Salmonella spp.), various mycobacterial strains (Mycobacterium fortuitum and Mycobacterium smegmatis), yeast (Candida albicans), and mold (Aspergillus fumigatus). None of the compounds showed antiviral or antimicrobial activity, except compounds 13 and 14 exhibited anti-human immunodeficiency virus-1 activity with EC50 values of 1.79 and 2.39 μM with Selectivity index = 18 and 4, respectively. On the other hand, compounds 7a and 7j showed a marked cytotoxicity against the human CD4+ lymphocytes (MT-4). Therefore, 7a and 7j were evaluated for their antiproliferative activity against two solid tumor-derived cell lines, which exhibited IC50 values of 8.1 ± 0.10 μM and 4.8 ± 0.08 μM against Hep-G2 cell lines, respectively.

Steric and electronic factors influence regio-isomeric thiazole formations between substituted benzothioamides and ethyl bromopyruvate

We observed unexpected thiazole 1B formation when 2,6- dichlorobenzothioamide 1 and ethyl bromopyruvate were reacted under basic conditions at elevated temperatures in ethanol. Thiazole 1B, regio-isomeric to that expected under conventional Hantzsch condi

New Aryl-1,3-thiazole-4-carbohydrazides, Their 1,3,4-Oxadiazole-2-thione, 1,2,4-Triazole, Isatin-3-ylidene and Carboxamide Derivatives. Synthesis and Anti-HIV Activity

A series of isatin-3-ylidene (6a-i) and arylthiazolyl-1,3,4-oxadiazole-2- thione derivatives 7a-i derived from arylthiazolyl carbohydrazide analogs 4a-i were synthesized. Analogously, coupling of 4f with various amino acid methyl esters in the presence of HOBt/DCC reagents afforded the carboxamide derivatives 9a-d. The newly synthesized compounds were assayed against HIV-1 and HIV-2 in MT-4 cells. All compounds are inactive, except compounds 9b and 9c which showed inhibition of HIV-1 with EC50 = 2:34 μgmL-1, and 1.12 μgmL-1 with therapeutic indexes (SI) of 9 and 1, respectively.

INHIBITORS OF HCV NS5B POLYMERASE

The present invention porivdes compounds of Formula I, compositons and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.

A catch-and-release strategy for the combinatorial synthesis of 4-acylamino-1,3-thiazoles as potential CDK5 inhibitors

Two-dimensional libraries of 4-acylamino-1,3-thiazoles 9 were prepared via Curtius rearrangement of 1,3-thiazole-4-carbonyl azides 6, trapping of the intermediate isocyanates with oxime resin, and thermal regeneration of the isocyanates from the washed resin in the presence of nucleophiles. Several compounds proved to be selective inhibitors of CDK5/p25 versus the closely homologous CDK2/cyclin A enzyme, with the best analogue (43) possessing over 100-fold selectivity.